Palatin Technologies Inc PTN
We take great care to ensure that the data presented and summarized in this overview for PALATIN TECHNOLOGIES INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PTN
View allLatest Institutional Activity in PTN
Top Purchases
Top Sells
About PTN
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
Insider Transactions at PTN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 01
2024
|
Stephen T Wills Executive VP and CFO/COO |
SELL
Open market or private sale
|
Direct |
4,999
-1.04%
|
$4,999
$1.66 P/Share
|
Jul 30
2024
|
Carl Spana President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
24,428
-1.11%
|
$24,428
$1.87 P/Share
|
Jul 30
2024
|
Stephen T Wills Executive VP and CFO/COO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,171
-0.81%
|
$16,171
$1.87 P/Share
|
Jul 15
2024
|
Arlene Morris |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+22.4%
|
-
|
Jul 15
2024
|
Anthony M. Manning |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+24.96%
|
-
|
Jul 15
2024
|
Stephen T Wills Executive VP and CFO/COO |
BUY
Grant, award, or other acquisition
|
Direct |
69,000
+18.87%
|
-
|
Jul 15
2024
|
Alan W Dunton |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+22.1%
|
-
|
Jul 15
2024
|
Joseph Stanley Hull |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+22.11%
|
-
|
Jul 15
2024
|
Carl Spana President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
79,000
+19.24%
|
-
|
Jul 15
2024
|
John K A Prendergast |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+20.17%
|
-
|
Jul 15
2024
|
Robert K Deveer Jr |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+23.97%
|
-
|
Jun 04
2024
|
Stephen T Wills Executive VP and CFO/COO |
BUY
Grant, award, or other acquisition
|
Direct |
28,990
+2.24%
|
-
|
Jun 04
2024
|
Carl Spana President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
33,201
+2.29%
|
-
|
Apr 11
2024
|
Robert K Deveer Jr |
BUY
Open market or private purchase
|
Direct |
6,000
+12.81%
|
$12,000
$2.12 P/Share
|
Mar 06
2024
|
Robert K Deveer Jr |
SELL
Open market or private sale
|
Direct |
11,700
-3.9%
|
$23,400
$2.01 P/Share
|
Dec 06
2023
|
Stephen T Wills Executive VP and CFO/COO |
SELL
Open market or private sale
|
Direct |
4,998
-0.75%
|
$9,996
$2.53 P/Share
|
Dec 04
2023
|
Alan W Dunton |
SELL
Open market or private sale
|
Direct |
200
-0.22%
|
$400
$2.47 P/Share
|
Aug 15
2023
|
Stephen T Wills Executive VP and CFO/COO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,088
-0.3%
|
$16,176
$2.21 P/Share
|
Aug 15
2023
|
Carl Spana President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,266
-0.41%
|
$24,532
$2.21 P/Share
|
Jun 20
2023
|
Stephen T Wills Executive VP and CFO/COO |
BUY
Grant, award, or other acquisition
|
Direct |
69,366
+3.68%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 286K shares |
---|---|
Open market or private purchase | 6K shares |
Open market or private sale | 16.7K shares |
---|---|
Payment of exercise price or tax liability | 40.6K shares |